Joel Greenblatt Xencor Inc Transaction History

Gotham Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.79 - $30.86 $288,357 - $358,963	11,632 New	11,632 $302,000
Q2 2022 Aug 15, 2022	SELL	$19.74 - $29.01 $223,772 - $328,857	-11,336 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$26.68 - $41.63 $142,924 - $223,011	5,357 Added 89.6%	11,336 $302,000
Q4 2021 Feb 14, 2022	SELL	$33.67 - $43.44 $30,067 - $38,791	-893 Reduced 12.99%	5,979 $240,000
Q3 2021 Nov 15, 2021	BUY	$30.65 - $35.68 $210,626 - $245,192	6,872 New	6,872 $224,000
Q1 2020 May 15, 2020	SELL	$20.69 - $37.79 $144,002 - $263,018	-6,960 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$32.75 - $41.43 $208,846 - $264,199	-6,377 Reduced 47.81%	6,960 $239,000
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $449,857 - $617,102	13,337 New	13,337 $450,000
Q1 2019 May 15, 2019	SELL	$27.85 - $38.09 $185,118 - $253,184	-6,647 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$32.39 - $42.05 $215,296 - $279,506	6,647 New	6,647 $240,000
Q4 2017 Feb 14, 2018	SELL	$19.29 - $24.83 $1.86 Million - $2.39 Million	-96,257 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $1.89 Million - $2.25 Million	96,257	96,257 $2.21 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.